|
| 4-amino-N-[(Z)-[5-(3-chlorophenyl)furan-2-yl]methylideneamino]-1,2,5-oxadiazole-3-carboxamide |
|
Brucella |
VirB type IV secretion system |
Preclinical (in vivo) |
Paschos A, et al. 2011. Infect Immun |
|
| N-(2-fluorophenyl)-4-methyl-3-(pyridin-4-ylmethylideneamino)-1,3-thiazol-2-imine |
|
Burkholderia |
Quorum-sensing |
Preclinical (in vitro) |
Christensen QH, et al. 2013. Proc Natl Acad Sci U S A |
|
| 4-(4-chlorophenyl)-2-[4-(2-phenyl-1,3-thiazol-4-yl)phenyl]-1,3-thiazole |
|
Enterococcus
Staphylococcus |
Others; Adherence; Biofilm
Others; Adherence; Biofilm |
Preclinical (in vitro)
Preclinical (in vitro) |
Oniga SD, et al. 2017. Molecules
|
|
| (4Z)-4-[(4-chlorophenyl)methylidene]-2-phenyl-5-(trifluoromethyl)pyrazol-3-one |
|
Haemophilus |
LOS |
Preclinical (in vitro) |
Xu Y, et al. 2018. Bioorg Med Chem |
|
| 1-[[5-tert-butyl-2-[(2,4-dichlorophenyl)methyl]pyrazole-3-carbonyl]amino]-3-phenylthiourea |
|
Mycobacterium |
Motility |
Preclinical (in vitro) |
Ouertatani-Sakouhi H, et al. 2017. PLoS One |
|
| 3-(tert-butyl)-1-(2,4-dichlorobenzyl)-1H-pyrazole-5-carbohydrazide |
|
Mycobacterium |
Motility |
Preclinical (in vitro) |
Ouertatani-Sakouhi H, et al. 2017. PLoS One |
|
| 3-(2-amino-1H-imidazol-5-yl)-N-[2-(4-bromophenyl)ethyl]propanamide;hydrochloride |
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Ballard TE, et al. 2008. Chemistry |
|
| 3,3,3-Tris(4-chlorophenyl)propionic acid |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Liang F, et al. 2003. J Biol Chem |
|
| | | |
| | | |
| | | |
| | | |
| | | |
